# Citrine Medicine

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/citrine-medicine

- Industry: Pharmaceuticals
- Headquarters: Shanghai, China
- Website: www.rarestonegroup.com
- Total disclosed funding: $80M
- Latest round: Series A (Jul 14, 2020)
- Investors on record: 4

## About

Founded in 2019 and based in Shanghai, China, Citrine Medicine operates as a pharmaceutical company that focuses on the development and production of rare disease drugs. It has 2 branch offices, which are Citrine Medicine and Zircon Health. In July 2020, Citrine Medicine raised a series A funding for USD 80 million led by new investor Quan Capital, with participation from other new investors F-Prime Capital, Eight Roads Ventures China, and Vivo Capital.


Citrine Medicine's main business is the development and commercialization of drugs for rare diseases. Its business can be categorized into pharmaceuticals and medical services. It has 8 rare disease drugs currently in the product pipeline, such as Wakix, Imcivree, and Efmody. Products can be used in the treatment of neuroscience, endocrine, and metabolic diseases. The company also provides services such as rare disease intelligence consultation, information inquiry, and knowledge dissemination.

The company generates revenue by providing rare disease drugs.

## Funding rounds

- Series A, Jul 14, 2020, $80M — Vivo Capital, Eight Roads Ventures, F-Prime Capital, Quan Capital

## Investors

- Vivo Capital (https://capitalatlas.ai/funds/vivo-capital) — Series A
- Eight Roads Ventures (https://capitalatlas.ai/funds/eight-roads-ventures) — Series A
- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series A
- Quan Capital (https://capitalatlas.ai/funds/quan-capital) — Series A